{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:26:42Z","timestamp":1774582002121,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shire"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bcmd.2014.02.006","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T08:45:17Z","timestamp":1393317917000},"page":"56-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up"],"prefix":"10.1016","volume":"53","author":[{"given":"Deborah","family":"Elstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Haims","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.02.006_bb0005","series-title":"Williams Hematology","first-page":"1065","article-title":"Lipid storage diseases","author":"Zimran","year":"2010"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0010","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0950-3536(97)80041-8","article-title":"Skeletal involvement in Gaucher's disease","volume":"10","author":"Elstein","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2014.02.006_bb0020","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","article-title":"Response of Gaucher bone disease to enzyme replacement therapy","volume":"75","author":"Poll","year":"2002","journal-title":"Br. J. Radiol."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2014.02.006_bb0025","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: a review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1148\/radiology.182.2.1732964","article-title":"Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease","volume":"182","author":"Johnson","year":"1992","journal-title":"Radiology"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0055","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1006\/bcmd.2001.0474","article-title":"Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease","volume":"27","author":"Hollak","year":"2001","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0065","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0070","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2214\/AJR.07.3550","article-title":"Correlation of MRI-based bone marrow burden score with genotype and spleen status in Gaucher's disease","volume":"191","author":"DeMayo","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0090","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2010.07.008","article-title":"Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease","volume":"46","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2011.04.005","article-title":"Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction","volume":"47","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2010.10.005","article-title":"Whole body MRI in type I Gaucher patients: evaluation of skeletal involvement","volume":"46","author":"Poll","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0130","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"27","author":"Khan","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0135","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2014.02.006_bb0140","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a Phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.02.006_bb0145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2012.11.001","article-title":"Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease","volume":"50","author":"van Dussen","year":"2013","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:34Z","timestamp":1761049834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979614000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1079979614000126"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.02.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}